

Therapeutic Products Programme
Holland Cross, Tower "B"
6th Floor, 1600 Scott Street
Address Locator # 3106B
OTTAWA, Ontario
K1A 1B6

October -20, 2000

00-100521 - 582

Mr. Anthony F. Stephan
Synergy Group of Canada Inc.
635-2 Avenue West
CARDSTON, Alberta
T0K 0K0

Dear Mr. Stephan:

This refers to your firm's involvement in studies conducted in various centers, including the University of Calgary, the University of Ottawa, the University of Alberta and the University of Lethbridge, using a product or combination of products called Synergy for use in various disorders, including schizophrenia, autism, fibromyalgia.

The *Food and Drugs Act and Regulations* require that an Investigational New Drug Submission (IND) be filed with the Therapeutic Products Programme for evaluation prior to initiating a clinical trial. The review of the IND submission is subject to a 60-day default period, and a "No Objection Letter" would be issued should the proposed clinical trial be considered satisfactory. According to our records, no authorization has been obtained for any studies involving a product or group of products under the name of Synergy, or Synergy Quad Nutrient Program, or E.M.POWER+ powder drink, tablets or capsules.

In addition, information on your website at www.truehope.com promoting treatment with Synergy prior to obtaining authorization to market the product in Canada is in violation of the *Food and Drugs Act and Regulations*.

Information on the Canadian legislation and related

.../2

000079

documents are available on the Health Canada Website at www.hc-sc.gc.ca/hpb-dgps/therapeut.

Your cooperation in filing for an authorization to conduct clinical studies in Canada is requested.

Yours sincerely,

Original signed by:

Robert G. Peterson, M.D. PhD. MPH
A/Director General

000080